|
ALK's Grazax in five-year landmark asthma prevention trial in children sees …
The Pharma Letter (registration) Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced disappointing top-line results from the Grazax Asthma Prevention (GAP) trial with ALK's allergy immunotherapy tablet against grass pollen allergy. The GAP trial consisted of a … |
View full post on asthma – Google News